Vadadustat

Vadadustat
Clinical data
Other names	AKB-6548, PG-1016548
ATC code	None;
Identifiers
	IUPAC name 2-([5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino)acetic acid;
CAS Number	1000025-07-9;
PubChem CID	23634441;
ChemSpider	34958379;
UNII	I60W9520VV;
CompTox Dashboard (EPA)	DTXSID501179936 ;
ECHA InfoCard	100.248.991
Chemical and physical data
Formula	C14H11ClN2O4
Molar mass	306.701 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Oc1cc(cnc1C(=O)NCC(=O)O)c2cccc(Cl)c2;

Vadadustat (INNTooltip International Nonproprietary Name) (AKB-6548) is a drug which acts as a HIF prolyl-hydroxylase inhibitor and thereby increases endogenous production of erythropoietin, which stimulates production of hemoglobin and red blood cells. It is in Phase III clinical trials for the treatment of anemia secondary to chronic kidney disease.^[1]^[2]^[3]

References

^ Pergola PE, Spinowitz BS, Hartman CS, Maroni BJ, Haase VH. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int. 2016 Nov;90(5):1115-1122. . doi:10.1016/j.kint.2016.07.019. PMID 27650732. {{cite journal}}: Cite journal requires |journal= (help); Missing or empty |title= (help)
^ Gupta N, Wish JB. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD. Am J Kidney Dis. 2017 Jun;69(6):815-826. . doi:10.1053/j.ajkd.2016.12.011. PMID 28242135. {{cite journal}}: Cite journal requires |journal= (help); Missing or empty |title= (help)
^ Martin ER, Smith MT, Maroni BJ, Zuraw QC, deGoma EM. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease. Am J Nephrol. 2017;45(5):380-388. . doi:10.1159/000464476. PMID 28343225. {{cite journal}}: Cite journal requires |journal= (help); Missing or empty |title= (help)

This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.